Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22863326 | 0.84 | APP (0.35) | APPALOX5NR1H4BACE1PTPN1 | |
| SCHEMBL29406722 | 0.84 | APP (0.35) | APPALOX5NR1H4BACE1PTPN1 | |
| SCHEMBL9880208 | 0.84 | APP (0.35) | APPALOX5NR1H4BACE1PTPN1 | |
| SCHEMBL15744228 | 0.84 | APP (0.35) | APPALOX5NR1H4BACE1PTPN1 | |
| SCHEMBL30645388 | 0.80 | CRBN (0.31) | PTPN1 | |
| SCHEMBL24619670 | 0.79 | APP (0.34) | APPNR1H4BACE1MAOBACHE | |
| SCHEMBL13746651 | 0.78 | APP (0.35) | APPALOX5NR1H4BACE1PTPN1 | |
| SCHEMBL23941477 | 0.76 | ALOX5 (0.37) | APPALOX5NR1H4BACE1PTPN1 | |
| SCHEMBL22863355 | 0.76 | ALOX5 (0.37) | APPALOX5NR1H4BACE1PTPN1 | |
| SCHEMBL13663953 | 0.75 | APP (0.36) | APPALOX5NR1H4BACE1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | APP 728/4885ALOX5 71/4885NR1H4 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.